The Crosstalk between Interferon and Transforming Growth Factor Beta Signaling Pathways in Hepatitis C Patients | ||||
| The Egyptian Journal of Hospital Medicine | ||||
| Article 4, Volume 72, Issue 10, July 2018, Page 5367-5370 PDF (258.08 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejhm.2018.11278 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Noha Mohamed Hany M. Elzeiny  1; Abd-El-Rahman M. A. Hammouda1; Enas Samir Nabih1; Sherif Monier Mohamed2
| ||||
| 1Medical Biochemistry and Molecular Biology departement, Faculty of Medicine, Ain Shams University | ||||
| 2Internal Medicine and Gastroenterology Department, Faculty of Medicine, Ain Shams University | ||||
| Abstract | ||||
| Background: there is an increasing interest in using microRNAs (miRNAs) as biomarkers in liver disease. Diagnostic biomarkers in hepatitis C serve as a great benefit for the early treatment of HCV. Aim of the Work: the aim of this study was to evaluate the expression of miRNA-16 in Egyptian patients infected with HCV and their relation to different biochemical and clinicopathological parameters. Patients and Methods: twenty-five subjects were chosen, 16 HCV infected and 9 healthy controls. Collection, processing and storage of serum for evaluation of miRNA16 using RT-qPCR was done. We evaluated the power of miRNA as a diagnostic tool using ROC curve analysis. The prognostic significance of the investigated parameters in HCV patients was explored. Results: there is a highly significant difference of miRNA 16 expression between HCV patients and healthy controls. miRNA 16 has great sensitivity and specificity for differentiating between patients with HCV and healthy controls. Conclusion: miRNA 16 can be used as a potential diagnostic biomarker for HCV. In addition, it could be used for staging of the disease. | ||||
| Keywords | ||||
| HCV; miRNA; miRNA 16 | ||||
|
Statistics Article View: 136 PDF Download: 297 |
||||
